The drug, branded as Antabuse but also sold as a generic called
disulfiram, was given to 30 HIV positive patients in America and
Australia who were already taking antiretroviral therapy (ART) AIDS
drugs.
At the highest given dose, there was evidence that "dormant HIV was
activated", the researchers said in a study published in The Lancet
HIV journal on Monday, and with no adverse effects.
Julian Elliott of the department of infectious diseases at The
Alfred in Melbourne, Australia, who worked with Lewin, said waking
up the virus was only the first step to eliminating it.
"The next step is to get these cells to die," he said.
HIV latency, where the virus remains dormant in the body in people
taking ART, is one of the biggest hurdles to achieving a cure for
the viral infection that causes AIDS. HIV/AIDS has killed some 34
million people since the 1980s, according to the United Nations HIV
program UNAIDS.
HIV can be held in check by ART, and by the end of 2014 an estimated
36.9 million people around the world were living with the virus.
Some 2 million people a year are newly infected.
Scientists say finding ways of "waking up" the virus in these
dormant cells and then destroying them is a key cure strategy, but
researchers have so far been unable to find the exact effective
combination of drugs.
Sharon Lewin, a University of Melbourne professor who led the work,
said that while scientists have made headway into activating latent
HIV, one of the main concerns is the toxicity of the drugs trailed.
[to top of second column] |
With disulfiram, however, this did not appear to present a problem,
she said.
"This trial clearly demonstrates that disulfiram is not toxic and is
safe to use, and could quite possibly be the game changer we need,"
she said in a statement.
"The dosage of disulfiram we used provided more of a tickle than a
kick to the virus, but this could be enough. Even though the drug
was only given for three days, we saw a clear increase in (the)
virus in (the) plasma, which was very encouraging."
(Reporting by Kate Kelland, editing by Angus Berwick and Ralph
Boulton)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|